Market News & Trends
Olema Oncology Announces New Clinical Trial Collaboration & Supply Agreement
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Novartis in frontline metastatic breast cancer. Olema has also entered into…
PTC Therapeutics Enters Global License & Collaboration Agreement With Novartis
PTC Therapeutics, Inc. recently announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:…
Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1
Ocular Therapeutix, Inc. recently announced more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI (axitinib intravitreal implant, also known…
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty & Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
XOMA Royalty Corporation recently announced it now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension (PAH), through…
NovelMed Receives FDA IND Approval for the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder
NovelMed recently announced the US FDA has granted clearance for Ruxoprubart, an investigational drug, to commence an efficacy trial for the treatment of Immunoglobulin A…
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation to R289 for the treatment of patients with previously-treated transfusion dependent lower-risk…
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology, Inc. recently announced the US FDA granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and…
Lin BioScience Receives FDA Fast Track Designation For LBS-007
Lin BioScience recently announced its lead pipeline, LBS-007, has been granted Fast Track Designation by the US FDA for the treatment of acute myeloid leukemia.…
Marinomed Biotech AG Signs Agreement for Sale of Carragelose Business to Unither Pharmaceuticals
Marinomed Biotech AG has signed an agreement on the sale of its Carragelose business to the French CDMO Unither Pharmaceuticals. The contract provides for upfront…
Nutriband Receives Patent Notice of Publication for its Abuse Deterrent Transdermal Technology
Nutriband Inc. recently announced it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong…
Anocca Announces Submission of Clinical Trial Application for Multi-Asset Trial VIDAR-1 in Advanced Pancreatic Cancer
Anocca AB recently announced the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase 1/2 multi-asset umbrella…
Greenwich LifeSciences Partners With GIM in Italy
Greenwich LifeSciences, Inc. recently announced its partnership with clinical sites in Italy. The company has partnered with Gruppo Italiano Mammella (GIM), the largest academic cooperative…
Hovione Expands Global Spray Drying Capacity With Significant Investment in the US & Ireland
Hovione just completed significant expansions in Europe and the US. The investments at its East Windsor, NJ, and Ringaskiddy, Cork, facilities will significantly increase Hovione's…
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Anavex Life Sciences Corp. recently announced the submission of the blarcamesine (ANAVEX2-73) MAA (Marketing Authorization Application) to the European Medicines Agency (EMA). The MAA submission…
Otsuka Submits NDA for Bempedoic Acid in the Treatment of Hypercholesterolemia
Esperion recently announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare…
Renexxion Ireland Announces Issuance of Fifth New US Patent Covering Novel Crystal Isoform of Naronapride
Renexxion Ireland Limited recently announced a major milestone in its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has granted the fifth…
Shuttle Pharma Expands Patient Enrollment for Phase 2 Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for…
ACG Launches Innovative Tablet Feeder
ACG Engineering, a division of ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, unveiled its new ADAPT X…
Gelteq Announces 400,000 Units Enter Production in November 2024
Gelteq Limited recently announced that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients…
Adragos Pharma Acquires Leading Swiss Sterile Fill-Finish Expert
Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step…
